A recent study finds that despite biosimilar use rising to 60% to 86% for three cancer drugs, predicted savings don’t match ...
Epkinly, Rituxan, and Revlimid combination reduces disease progression risk by 79% in relapsed/refractory follicular lymphoma patients. The EPCORE FL-1 trial supports global regulatory submissions and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback